|Have Questions?||Leave a Message or Start an on-line Chat|
In the preparation of this PD-L1 monoclonal antibody, mouses were selected as the host animal. A Recombinant Human Programmed cell death 1 ligand 1 protein was injected into the mouse to immunize it. Next, the spleen cells were removed from the mouse and fuse B cells in the spleen cells with myeloma cells, using the hybridoma technology. And the hybridoma was obtained in the process, which was featured with the properties of growing in culture and producing PD-L1 monoclonal antibody. This PD-L1 antibody has been purified by Protein G and validated in ELISA, WB, IHC, IF, FC.PD-L1 (Programmed death-ligand 1), also known as CD274 or B7 homolog 1 (B7-H1), is encoded by the CD274 gene. PD-L1 is a class I transmembrane protein with a size of 40 kDa, with a total length of 290 amino acids, including an IgV-like region, an IgC-like region, a transmembrane hydrophobic region and an intracellular region. PD-L1 is the ligand of PD-1, which is commonly expressed in antigen-presenting cells, macrophages, activated T cells, B cells, monocytes, endothelial cells, etc.
Immune checkpoints include CTLA4-CD80, PD-1-PD-L1/PD-L2, GAL9-TIM3, etc., among which PD-1-PD-L1 has become a research hotspot in tumor immunity in recent years. PD-1 is an important negative regulatory molecule for immune cell activation. By combining with PD-L1, it produces a variety of biological effects such as inhibiting the proliferation and activation of lymphocytes, inhibiting the release of cytokines, etc., thereby exerting immunosuppressive effects. Through the high expression of PD-1 and PD-L1, tumor cells go through the three processes of clearance, balance, and escape of the immune microenvironment, and eventually may escape the body's immune system and form tumors.
B7 H antibody; B7 H1 antibody; B7 homolog 1 antibody; B7-H1 antibody; B7H antibody; B7H1 antibody; CD 274 antibody; CD274 antibody; CD274 antigen antibody; CD274 molecule antibody; MGC142294 antibody; MGC142296 antibody; OTTHUMP00000021029 antibody; PD L1 antibody; PD-L1 antibody; PD1L1_HUMAN antibody; PDCD1 ligand 1 antibody; PDCD1L1 antibody; PDCD1LG1 antibody; PDL 1 antibody; PDL1 antibody; Programmed cell death 1 ligand 1 antibody; Programmed death ligand 1 antibody; RGD1566211 antibody
|Immunogen||Recombinant Human Programmed cell death 1 ligand 1 protein (19-238AA)|
|Immunogen Species||Homo sapiens (Human)|
|Purification Method||>95%, Protein G purified|
|Concentration||It differs from different batches. Please contact us to confirm it.|
|Buffer||Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
|Tested Applications||ELISA, WB, IHC, IF, FC|
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol
|Troubleshooting and FAQs||Antibody FAQs|
|Storage||Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.|
|Lead Time||Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.|
Applications : Western Blot (WB)
Sample type: Human granulosa cell carcinoma KGN
Sample dilution: 1:1500
Review: The antibody strip is correct, but there is a weak band nearby. The technician suggests that experiment steps are to be optimized.
Applications : Western Blot (WB)
Review: To investigate whether PD-L1 expression is involved in the biological activities of leukemic cells, siRNA knockdown of PD-L1 expression in KG-1a via western blot analysis showed high expression of PD-L1.
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
|Gene References into Functions||
|Subcellular Location||Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein.|
|Protein Families||Immunoglobulin superfamily, BTN/MOG family|
|Tissue Specificity||Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.|